PLUS THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.2M | $5.8M | $4.9M | — | — |
| Operating income | -$15.3M | -$14.7M | -$13.3M | -$19.7M | -$12.5M |
| Operating expenses | $20.5M | $20.5M | $18.2M | $19.9M | $12.5M |
| Cash from operations | -$20.8M | -$10.6M | -$12.9M | -$13.0M | -$10.3M |
| Capital expenditure | $67,000 | $146,000 | $160,000 | — | — |
| Free cash flow | -$20.8M | -$10.7M | -$13.0M | — | — |
| Share repurchases | — | $374,000 | $126,000 | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $16.3M | $6.6M | $11.4M | $23.9M | $22.0M |
| Total liabilities | $12.3M | $15.6M | $12.7M | $17.4M | $11.1M |
Shares outstanding 6.9M · Free float 23.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.